Compare Brookfield Infrastructure Partners LP (BIP) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brookfield Infrastructure Partners LP vs Sana Biotechnology Inc — how do they compare? Brookfield Infrastructure Partners LP trades at $39.54 (market cap $18.10B), while Sana Biotechnology Inc trades at $3.77 (market cap $1.13B). The key difference: Brookfield Infrastructure Partners LP is far larger — about 16× Sana Biotechnology Inc's market cap, and Brookfield Infrastructure Partners LP pays a 4.62% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| BIP | SANA | |
|---|---|---|
Market Cap | $18.10B | $1.13B |
Sector | Industrials | Health |
52-Week High | $42.62 | $5.92 |
52-Week Low | $29.81 | $2.68 |
Enterprise Value | $77.05B | $1.05B |
Dividend Yield | 4.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Brookfield Infrastructure Partners (BIP) trades at $39.55, up 4.13% in the last session, with a bullish technical signal and strong analyst support. Recent earnings misses contrast with positive cash flow trends and a 6.97 EV/EBITDA valuation. News highlights dividend appeal and corporate simplification efforts, while institutional interest remains robust.
Outlook is cautiously optimistic given high analyst buy ratings and a $44.67 price target, but risks include earnings volatility and margin pressure. The stock offers income potential with dividends, though net income declined to $652M in 2026. Investors should weigh solid infrastructure assets against execution challenges.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
